Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer cell receptor NKG2D is a transmembrane activating receptor expressed primarily on NK cells and subsets of T cells (notably CD8+ T, γδ T, and disease-activated CD4+ T cells in humans)[1][5][3]. It belongs to the C-type lectin-like receptor family and is encoded by the KLRK1 gene. NKG2D recognizes "induced-self" ligands—mainly MICA, MICB, and ULBP family members in humans—whose expression is upregulated on the surface of cells under cellular stress, transformation (cancer), infection, or DNA damage. When engaged by these ligands, NKG2D triggers potent cytotoxicity and cytokine secretion, contributing to immune surveillance and the elimination of malignant or infected cells. Signal transduction requires association with the adaptor protein DAP10 in humans, and both DAP10 and DAP12 in mice, relying on downstream effectors like PI3K, Vav1, and Syk/ZAP70 kinases for intracellular signaling[1][5][3]. NKG2D functions as a *master regulator* of immune cell activation thresholds—coordinating responses by integrating activating and inhibitory signals, and is central to innate and adaptive immunity[3]. Its role is implicated in cancer immunotherapy, infection defense, autoimmunity, and transplant biology, though modulation of its pathway carries notable safety challenges[5][3][6][2][8].
Activation of NK cell-mediated cytotoxicity via ligand engagement on transformed, infected, or stressed cells[5][1][3]. Co-stimulatory signaling for T cell activation[1][3]. Initiation of cytokine secretion such as IFN-gamma and GM-CSF[2][5].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell receptor NKG2D (NKG2D).